| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 43% Percent agreement (class: benign) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceOncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, benign_concordance; subgroup values correspond to Supplemental Table S6 |
|---|
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 78% Percent agreement percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceOncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, concordance; subgroup values correspond to Supplemental Table S6 |
|---|
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 78.2% Percent agreement (variant type: missense) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceOncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, missense_concordance; subgroup values correspond to Supplemental Table S6 |
|---|
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 82.5% Percent agreement (gene role: oncogene) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceOncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, oncogene_concordance; subgroup values correspond to Supplemental Table S6 |
|---|
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 79% Percent agreement (oncogenic vs pathogenic) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceOncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, oncogenic_vs_pathogenic_concordance; subgroup values correspond to Supplemental Table S6 |
|---|
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 49.4% Percent agreement (variant type: truncating) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceOncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, truncating_concordance; subgroup values correspond to Supplemental Table S6 |
|---|
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 76% Percent agreement (gene role: tumour suppressor) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceOncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, tsg_concordance; subgroup values correspond to Supplemental Table S6 |
|---|
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 97% Percent agreement (class: VUS) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceOncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, vus_concordance; subgroup values correspond to Supplemental Table S6 |
|---|